Parabilis Medicines, Inc. Common Stock (PBLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Parabilis Medicines, Inc. Common Stock (PBLS) has a cash flow conversion efficiency ratio of -0.201x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-49.20 Million) by net assets ($244.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View Parabilis Medicines, Inc. Common Stock stock price for real-time trading data and today's change.
Parabilis Medicines, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Parabilis Medicines, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see market value of Parabilis Medicines, Inc. Common Stock for the company's overall valuation and market capitalisation.
Parabilis Medicines, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Parabilis Medicines, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see PBLS current and non-current assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Diodes Incorporated
NASDAQ:DIOD
|
0.034x |
|
Miami International Holdings, Inc.
NYSE:MIAX
|
0.107x |
|
Almonty Industries Inc. Common Shares
NASDAQ:ALM
|
0.027x |
|
Page Industries Limited
NSE:PAGEIND
|
0.356x |
|
Aster DM Healthcare Limited
NSE:ASTERDM
|
0.066x |
|
ViTrox Corporation Bhd
KLSE:0097
|
0.029x |
|
Nanjing Iron & Steel Co Ltd
SHG:600282
|
0.018x |
|
Grupo Aeroportuario del Centro Norte S.A.B. de C.V
MX:OMAB
|
0.190x |
Annual Cash Flow Conversion Efficiency for Parabilis Medicines, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Parabilis Medicines, Inc. Common Stock from 2024 to 2025. Review financial flexibility index of Parabilis Medicines, Inc. Common Stock to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-16.52 Million | $-123.71 Million | 7.487x | +507.82% |
| 2024-12-31 | $56.44 Million | $-103.61 Million | -1.836x | -- |
About Parabilis Medicines, Inc. Common Stock
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein … Read more